


AMENDMENTS TO THE CLAIMS

1. (Previously presented) A peptide represented by the general formula I:



or a pharmaceutically acceptable salt thereof,

wherein, if a is 1 then b is 0;

if a is 0 then b is 1;

z is 4;

p is 1, x and q are 0, and y is 1;

d is 0;

wherein R₁ is the amino acid side chain of glycine;


wherein R₂ is selected from the group consisting of NH₂, NHR, NR₂, NR₃⁺H, OH, SH, RO, RS, RSO, RSO₂, COR, CSR, COOH, COOR, CONH₂, CONHR, CONR₂, OCOR, and SCOR, wherein R is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl;

wherein R_3 is H or CH_3 ; and

wherein R_x is a hydrophobic group.

2-55. (Cancelled)

56. (Previously presented) The peptide of claim 1, wherein said peptide is represented by general formula II:



or a pharmaceutically acceptable salt thereof,

wherein R_4 and R_5 are independently selected from the group consisting of H, alkyl, alkenyl, aryl, aralkyl, halogen, CN, NO_2 , alkoxy, aryloxy, aralkyloxy, thioalkoxy,

thioaryloxy, thioaralkyloxy, $+S(CH_3)_2$, SO_3H , SO_2R , NH_2 , NHR , NR_2 , $+NR_3$, OH , SH , $COOH$, $COOR$, $CONH_2$, $CONHR$, $CONR_2$, CH_2OH , NCO , $NCOR$, $NHOH$, $NHNH_2$, $NHNHRH$, CH_2OCOR , CH_2OCSR , COR , CSR , $CSOR$, CF_3 , and CCl_3 , and wherein R is alkyl, alkenyl, aryl, aralkyl, or cycloalkyl.

57. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide comprises at least one D amino acid.

58-60. (Cancelled)

61. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein R_x comprises an aromatic carbon ring.

62. (Previously presented) The peptide of claim 61, or a pharmaceutically acceptable salt thereof, wherein said aromatic carbon ring comprises a 6 or 12 membered ring or a substituted form thereof.

63. (Previously presented) The peptide of claim 62, or a pharmaceutically acceptable salt thereof, wherein said ring is substituted with at least one selected from the group consisting of a lower alkyl, alkoxy, hydroxyl, carboxy, amine, thiol, hydrazide,

amide, halide, hydroxyl, ether, amine, nitrile, imine, nitro, sulfide, sulfoxide, sulfone, thiol, aldehyde, keto, carboxy, ester, amide, seleno, and thio, or a derivative thereof.

64. (Previously presented) The peptide of claim 63, or a pharmaceutically acceptable salt thereof, wherein said ring comprises 1 or 2 substitutions.

65. (Previously presented) The peptide of claim 62, or a pharmaceutically acceptable salt thereof, wherein said ring is selected from the group consisting of a benzyl, phenyl, and naphthyl, or a substituted form thereof.

66. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide comprises a free N-terminal, a free C-terminal, or both a free N- and C-terminal.

67. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said hydrophobic group is a 6-membered aromatic carbon ring comprising a substituent at the 4-position.

68. (Previously presented) The peptide of claim 67, or a pharmaceutically acceptable salt thereof, wherein said substituent is selected from the group consisting of alkyl, alkoxy, hydroxyl, carboxy, amine, thiol, hydrazide, amide, halide, hydroxyl, ether,

amine, nitrile, imine, nitro, sulfide, sulfoxide, sulfone, thiol, aldehyde, keto, carboxy, ester, amide, seleno, and thio, or a derivative thereof.

69. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide is an orally available peptide.

70. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide has a half-life in an *in vitro* plasma stability assay of more than about 30 minutes.

71. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide has a half-life in an *in vitro* plasma stability assay of more than about 48 hours.

72. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide binds to a tissue, cell, or cell fraction that is a site of action for an antiarrhythmic peptide.

73. (Currently amended) The peptide of claim 72, or a pharmaceutically acceptable salt thereof, wherein said antiarrhythmic peptide ~~agonized~~ agonizes or antagonizes the function of AAP, AAP10, HP5, or a functional analog thereof.

74. (Cancelled)

75. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide is selected from the group consisting of H-D-Lys(2,4-dinitrobenzoyl)-Gly-OH (Compound 103), H-D-Lys(2,4-dimethylbenzoyl)-Gly-OH (Compound 104), H-D-Lys(2,5-dimethylbenzoyl)-Gly-OH (Compound 105), H-D-Lys(3,5-dimethylbenzoyl)-Gly-OH (Compound 106), H-D-Lys(2,4-dichlorobenzoyl)-Gly-OH (Compound 107), H-D-Lys(2,5-dichlorobenzoyl)-Gly-OH (Compound 108), H-D-Lys(4-fluoro-3-nitrobenzoyl)-Gly-OH (Compound 109), and H-D-Lys(3-fluoro-4-methylbenzoyl)-Gly-OH (Compound 110).

76. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide is selected from the group consisting of H-Gly-D-Lys(4-methoxybenzoyl)-OH (Compound 12), H-Gly-D-Lys(4-nitrobenzoyl)-OH (Compound 13), H-Gly-D-Lys(4-fluorobenzoyl)-OH (Compound 14), H-Gly-D-Lys(4-cyanobenzoyl)-OH (Compound 15), H-Gly-D-Lys(4-nitrobenzoyl)-OH (Compound 16), and H-Gly-D-Lys(benzoyl)-OH (Compound 17).

77. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide is selected from the group consisting of H-

D-Lys(4-methoxybenzoyl)-Gly-OH (Compound 21), H-D-Lys(4-nitrobenzoyl)-Gly-OH (Compound 22), H-D-Lys(benzoyl)-Gly-OH (Compound 23), H-D-Lys(4-fluorobenzoyl)-Gly-OH (Compound 24), H-D-Lys(4-cyanobenzoyl)-Gly-OH (Compound 25), and H-D-Lys(4-chlorobenzoyl)-Gly-OH (Compound 26).

78. (Previously presented) The peptide of claim 77, or a pharmaceutically acceptable salt thereof, wherein said peptide is selected from the group consisting of H-D-Lys(4-methoxybenzoyl)-Gly-OH (Compound 21), H-D-Lys(4-nitrobenzoyl)-Gly-OH (Compound 22), and H-D-Lys(benzoyl)-Gly-OH (Compound 23).

79. (Previously presented) The peptide of claim 1, or a pharmaceutically acceptable salt thereof, wherein said peptide is selected from the group consisting of H-D-Lys(4-phenoxybenzoyl)-Gly-OH (Compound 53), H-D-Lys(4-t-butylbenzoyl)-Gly-OH (Compound 54), H-D-Lys(4-n-butoxybenzoyl)-Gly-OH (Compound 55), H-D-Lys(4-methylbenzoyl)-Gly-OH (Compound 56), H-D-Lys(4-ethylbenzoyl)-Gly-OH (Compound 57), H-D-Lys(4-n-butylbenzoyl)-Gly-OH (Compound 58), H-D-Lys(4-n-hexylbenzoyl)-Gly-OH (Compound 59), H-D-Lys(4-n-octylbenzoyl)-Gly-OH (Compound 60), H-D-Lys(4-phenylbenzoyl)-Gly-OH (Compound 61), H-D-Lys(4-benzyloxybenzoyl)-Gly-OH (Compound 62), and H-D-Lys(4-ethoxybenzoyl)-Gly-OH (Compound 63).

80. (Previously presented) The peptide of claim 79, or a pharmaceutically acceptable salt thereof, wherein said peptide is H-D-Lys(4-t-butylbenzoyl)-Gly-OH (Compound 54).

81-82. (Cancelled)

83. (Previously presented) A pharmaceutical composition comprising a peptide of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.

84. (Previously presented) The pharmaceutical composition of claim 83, wherein said composition is orally administrable.

85. (Previously presented) A method of treating arrhythmia comprising administering to a patient in need thereof a therapeutically effective amount of a peptide of claim 1, or a pharmaceutically acceptable salt thereof.

86. (Previously presented) The method of claim 85, wherein said arrhythmia is bradyarrhythmia or tachyarrhythmia.

87. (Previously presented) The method of claim 85, wherein said arrhythmia is atrial arrhythmia.

88. (Previously presented) The method of claim 85, wherein said arrhythmia is ventricular arrhythmia.

89. (Currently amended) H-D-Lys(4-nitrobenzoyl)-Gly-OH (Compound 22), or a pharmaceutically acceptable salt thereof.